Untitled Letter

Lipitor.com gets Bad Ad slap for cross-promotion sans risk info

September 06, 2011

Pfizer's Lipitor website touted the efficacy of Caduet, Chantix and Norvasc but failed to balance those claims with risk info for the drugs, according to an "untitled letter" from FDA's Division of Drug Marketing, Advertising and Communication (DDMAC).
 

Boniva print ad hyped efficacy, says DDMAC

January 26, 2011

A print ad for Genentech's Boniva overstated the osteoporosis drug's efficacy, said the FDA's Division of Drug Marketing, Advertising and Communication in an untitled letter.
 

DDMAC enforcement letters up 26% in 2010

December 28, 2010

The FDA's Division of Drug Marketing, Advertising and Communications has written 26% more enforcement letters to drug companies over promotional practices this year than it did in 2009.
 

DDMAC pokes Allergan on eye drop direct mail

December 07, 2010

Allergan has a superiority complex when it comes to marketing its ophthalmic drops, as evidenced by a second DDMAC Untitled Letter posted online yesterday.
 

DDMAC slaps Alcon convention graphic

October 26, 2010

A convention graphic for Alcon's Travatan Z, an ophthalmic drop, broadened the product's indication and made unsubstantiated superiority claims, according to a Division of Drug Marketing, Advertising and Communications (DDMAC) Untitled Letter.
 

DDMAC slaps Premarin patient testimonials, Acuvail journal ad

September 14, 2010

Patient testimonial videos on the brand.com homepage for Wyeth's (now Pfizer's) Premarin overstated the drug's efficacy and minimized risks, while a journal ad for Allergan's Acuvail made unsubstantiated superiority claims, overstated efficacy, broadened the drug's indication, and omitted risk information, according to a pair of untitled DDMAC letters.
 

Dendreon draws CBER letter for Provenge professional marketing

August 10, 2010

The Center for Biologics Evaluation and Research hit Dendreon with an untitled letter for false and misleading professional marketing materials for its prostate cancer treatment Provenge.
 

Novartis Facebook Share widget provokes DDMAC letter

August 05, 2010

A Facebook Share widget found on Novartis' Tasigna website provoked a DDMAC Untitled Letter, the fourth DDMAC communiqué Novartis has received this year.
 

Intuniv patient kit draws DDMAC untitled letter

June 30, 2010

Patient materials for Shire's ADHD drug Intuniv presented unsubstantiated effectiveness and superiority claims and downplayed important risk info, said the FDA's Division of Drug Marketing, Advertising and Communication.
 

Sepracor's 'boxing bed' ad hit with DDMAC untitled letter

June 21, 2010

A 60-second TV ad for insomnia drug Lunesta, which portrayed a woman fighting for sleep in a bed-turned-boxing ring, drew an untitled letter from regulators.
 

GSK awareness ad for Arzerra a stealth product promotion, says FDA

April 19, 2010

The FDA scolded GlaxoSmithKline over a disease-awareness ad that failed to mention side effects but alluded to newly approved cancer treatment Arzerra. It's a sign the agency is construing the exemption for disease-awareness promotions quite narrowly.
 

FDA says competing biologic ads both misled

April 07, 2010

One is a sales aid, and one is a consumer brochure, but both ads -- for CSL Behring's Zemaira and for Talecris' Prolastin -- are false or misleading, FDA said in a pair of untitled letters.
 

Video Exclusive

Web Exclusives

Five industry experts advise specialty pharma company on digital strategy

April 20, 2012

Specialty pharma company POZEN assembled a crack team of experts to help shape its digital strategy. Not only did POZEN share with us the text from their contributions, but you can watch exclusive video clips of their valuable perspectives right here.
 

MM&M Awards 2011 HIghlights

The Best MM&M Awards Ever!

MAHF Ceremony 2012

Photos from the Medical Advertising Hall of Fame Awards ceremony
 
Popular Topics
Acquisition Adherence Advertising App Celebrity Clinical Trial Co-Marketing Diabetes Diagnostics Digital Direct To Consumer (DTC) Disease Awareness Downsize DTC Education & Awareness FDA Food FTC Government Guidance Health Plans HMOs Hospitals Marketing Research Sales Force